Serologic Testing for Lyme Disease

Also in This Issue
A Brief Update: New Test Offerings in DNA-Based Non-Invasive Prenatal Testing (NIPT)

“Quality in Laboratory Diagnosis”
We frequently receive calls regarding recommendations for Lyme disease testing. Due to recent minor changes to our Lyme disease test menu, we are taking this opportunity to clarify recommended approaches for the serologic evaluation of patients suspected to have Lyme disease.

Lyme disease is the clinical syndrome caused by infection with the bacterial spirochete *Borrelia burgdorferi*. Infection by *B. burgdorferi* is transmitted via the North American deer tick (*Ixodes* sp). In its initial phase, Lyme disease typically is characterized by a distinct pattern of rash known as erythema migrans (EM).1,2 The incubation period between initial exposure and onset of EM varies considerably, but typically is about one to two weeks.3

In the acute phase of infection, the rash may be accompanied by systemic symptoms such as fever, joint and muscle pain, generalized weakness or fatigue, and enlarged lymph nodes.

If left untreated, Lyme disease may progress beyond the initial localized cutaneous phase into disseminated phases of disease.

The early disseminated phase of disease may be marked by multifocal EM type rashes that occur days or weeks after initial exposure. It also may be marked by neurologic symptoms such as facial nerve palsy (Bell’s palsy), arthritis, or meningitis.

*Borrelia burgdorferi*
Testing should only be performed when there is sufficient clinical suspicion. Wide-spread screening in the absence of pre-test suspicion increases false positives and adversely affects the performance of the testing algorithm.

If untreated, over half of patients will progress to a late disseminated phase, often marked by intermittent bouts of severe arthritis. A small minority of untreated patients will develop chronic neurologic symptoms such as pain or tingling in the hands and feet, or a mild encephalopathy manifest as difficulty in concentration, or deficits in memory.3

About 10 to 20% of patients will continue to have symptoms after a full course of antibiotic therapy for Lyme disease, a pattern referred to as post-treatment Lyme disease syndrome.2, 3

The cause of this syndrome is likely related to some combination of residual tissue damage and autoimmune phenomena, and not to continuing active infection. This is an important point, since continuing antibiotic therapy in patients with post-treatment Lyme disease syndrome is generally not indicated, and may actually be detrimental. In a vast majority of patients, these symptoms eventually clear, but ultimate resolution may take weeks or months.3

Laboratory Evaluation of Suspected Lyme Disease

Before discussing recommended laboratory tests, it is important to note that Lyme disease serologic testing should only be performed on individuals for whom there is sufficient clinical suspicion for Lyme disease based on clinical history, physical examination findings, and presence in an area endemic for Lyme disease.1, 3

As is the case with many clinical tests, wide-spread serologic screening in the absence of pre-test suspicion adversely affects the performance characteristics of the testing algorithm, and increases the incidence of false positive results.4

<table>
<thead>
<tr>
<th>Initial Localized Phase</th>
<th>Early Dissemination Phase</th>
<th>Late Dissemination Phase</th>
<th>Post-Treatment Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Localized infection</td>
<td>• Multiple rashes</td>
<td>• Recurrent arthritis</td>
<td>• Continuation of</td>
</tr>
<tr>
<td>• Solid red or distinctive bulls-eye rash</td>
<td>• Cranial nerve palsy</td>
<td>• Neurological disorders; confusion, dizziness, disorientation, short-term memory loss</td>
<td>symptoms after full course of antibiotics; arthritis, peripheral neuropathy, leukoencephalitis, encephalopathy, fatigue</td>
</tr>
<tr>
<td>• Flulike symptoms; muscle and joint pain, headache, fatigue</td>
<td>• Meningitis</td>
<td>• Peripheral neuropathy; pain and tingling in hands and feet</td>
<td></td>
</tr>
<tr>
<td>• Regional lymphadenopathy</td>
<td>• Joint and muscle pain, fever, headache, stiff neck, vision problems, sore throat, fatigue, lymphadenopathy</td>
<td>• Rarely; heart complications</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Rarely; heart complications</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Serologic Testing for Lyme Disease

The Warde Report
Volume 24, Issue 2, 2014

3
For patients with clinical signs, symptoms, and history suspicious for Lyme disease, the current standard is a two-tiered serologic approach, originally proposed at a multiagency consensus conference in 1995, and still endorsed by the Centers for Disease Control and Prevention (CDC) (Figure 1).1,3

The first tier involves enzyme immunoassay (ELISA)-based screening for both IgM and IgG antibodies against *B. burgdorferi*. At Warde Medical Laboratory, we offer a combined IgG / IgM (“total”) screen on the DiaSorin Liaison platform that targets the immunodominant *Borrelia* antigen V1SE (variable major protein-like sequence expressed) (Warde test code: LYME).1

Previously, some laboratories were offering separate initial ELISA evaluations for IgM antibodies and for IgG antibodies, and this option was available through Warde. However, CDC recommends testing for both antibody types at initial evaluation, and there is no particular advantage in separating these analyses at initial diagnosis.

Inclusion of IgM antibodies in the combined (total) serologic screen enhances sensitivity of the assay, since IgM may be present early in the course of infection relative to IgG. However, since both IgM and IgG antibodies may wax and wane, and since IgM antibodies may be present years or
The presence of IgM antibodies alone does not necessarily indicate more recent infection — IgM antibodies may be present years or decades after initial infection.

**Limitations of Screening**

Serologic testing for Lyme disease is sometimes criticized as being insensitive, but it is important to recognize the performance characteristics of these tests in appropriate clinical context.

It is true that in the earliest phase of the disease, sensitivity is relatively low since antibodies take time to develop. That is why initial treatment for acute Lyme disease is often started empirically based on presentation with characteristic clinical findings (such as EM) in an area endemic for Lyme disease.1

In general, the more time passes, the higher the sensitivity of the assay. According to Johnson,1 while perhaps 60% of patients with EM will test positive with modern assays on initial Lyme serology, the detection rate for these assays climbs to nearly 100% in some studies after the EM phase of the disease, or after the first 30 days following initial infection. Similarly, specificity of the recommended two-tiered approach in patients at 30 days duration of disease or longer likely exceeds 95%.7

Serologic Testing for Lyme Disease
It is also important to follow the testing algorithm as written. While the use of immunoblot / Western blot methods enhances specificity, the use of immunoblots on patients who have not been initially screened using ELISA methods results in high false positive rates, and decreases in test specificity. This is particularly true for IgM-based blots, which rely on the demonstration of fewer individual bands for a positive tests than IgG-based Western blots, and which are generally more prone to cross-reactivity.¹

Summary

Lyme disease testing should only be sought in patients for whom there is appropriate clinical suspicion for active Lyme disease (either acute or disseminated phase) based on clinical history, signs, and symptoms. Clinicians should use appropriate judgment for possible empiric treatment for patients who present with the classic erythema migrans rash in areas endemic for Lyme disease, as this phase of the disease may be difficult to confirm using laboratory methods.

For laboratory evaluation of Lyme disease, the CDC recommends a two-tier diagnostic approach. The first tier includes ELISA-based detection of IgM and IgG antibodies in a single combined assay (Warde test code LYME). A positive or equivocal ELISA screen should be followed up by an immunoblot-based method (Warde test code LYMEGMSP).

References

In a previous Warde Report, we introduced the Panorama non-invasive prenatal screening test (NIPT) as an option for our clients. In partnership with Panorama, we are now happy to offer additional options for NIPT. In addition to the existing screen for aneuploidy (trisomy 21, trisomy 18, trisomy 13, and monosomy X), Panorama now offers a screening panel for congenital syndromes related to specific chromosomal microdeletions, including DiGeorge syndrome (deletion 22q11.2), Angelman and Prader-Willi syndromes (deletion of portions of chromosome 15q), Cri-du-chat syndrome (deletion of a portion of chromosome 5p), and the 1p36 deletion syndrome.

Unlike fetal aneuploidy, these microdeletion syndromes are not a function of maternal age and have a consistent populational frequency across maternal age groups. In aggregate, these syndromes have a combined incidence of approximately 1 in 1,000 live births.

The most common of these syndromes (DiGeorge syndrome) affects approximately 1 in 2,000 live births, likely exceeding the incidence of cystic fibrosis. When filling out the required requisition / information sheet, practitioners will now have a choice as to whether to include microdeletion screening in addition to aneuploidy screening when ordering the Panorama NIPT (Warde test code: PANOR). According to the manufacturer, microdeletion analysis through the Panorama assay offers detection rates of 93 to 99%, depending on the specific deletion.

Microdeletion analysis will now be offered as a separate additional option, with a separate charge. As a result, the base price of the Panorama NIPT screen for aneuploidy has been reduced. For additional information, please contact Warde client services.

References

Are you ready to lower the cost of your reference testing?

Now you have a choice. You can work with a laboratory whose mission is mandated by the need for ever-increasing quarterly earnings. Or, you can work with Warde Medical Laboratory, where the physician-owners believe that principles are just as important as profits.

Exceptional People.
Exceptional Quality.
Exceptional Service.

Our purpose to provide critical information to healthcare practitioners is supported by our team of distinguished medical professionals. Working under the guidance of internationally known pathologists with impeccable reputations, our clinical specialists bring their particular expertise to test selection and interpretation. The result is an exceptional level of quality and outstanding customer service.

For more information about how Warde Medical Laboratory can provide exceptional quality and service while lowering the cost of your reference testing, please contact:

Jon T. Sanford, Business Development Manager
Office: 800-876-6522 | Mobile: 517-394-3222
sanfordjt@trinity-health.org | www.wardelab.com